Fig 1.
Fig 2.
Fig 3.
Fig 4.
Mean values of specific clinical parameters in the assessed patient groups
| Creatinine (mg/dL) | Proteinuria (g/24 h) | Total protein (g/dL) | Total albumin (g/dL) | Age (years) | |
|---|---|---|---|---|---|
| Membranous glomerulonephritis | 1.37 ± 0.57 | 4.23 ± 4.58 | 4.81 ± 0.70 | 2.79 ± 0.64 | 52.00 ± 12.00 |
| Focal segmental glomerulosclerosis | 1.32 ± 0.53 | 3.17 ± 3.11 | 5.20 ± 1.16 | 2.99 ± 0.91 | 46.36 ± 15.00 |
| Systemic lupus erythematosus | 1.21 ± 0.42 | 1.85 ± 1.70 | 5.60 ± 0.84 | 3.18 ± 0.59 | 37.82 ± 13.00 |
| IgA nephropathy | 1.19 ± 0.34 | 1.44 ± 1.29 | 5.57 ± 0.77 | 3.32 ± 0.64 | 43.86 ± 15.00 |
| Mesangial proliferative glomerulonephritis without IgA deposits | 1.01 ± 0.36 | 3.16 ± 2.54 | 4.68 ± 0.51 | 2.54 ± 0.61 | 31.50 ± 13.00 |
| c-ANCA vasculitis | 2.07 ± 1.54 | 1.72 ± 3.61 | 6.29 ± 0.44 | 3.63 ± 0.46 | 55.00 ± 18.00 |
| p-ANCA vasculitis | 3.93 ± 2.39 | 2.46 ± 3.08 | 6.09 ± 0.85 | 3.53 ± 0.42 | 62.00 ± 12.00 |
| Control group | 1.1 ± 0.25 | 0.00 ± 0.00 | 7.45 ± 0.85 | 4.40 ± 0.90 | 46.00 ± 13.00 |
Median and mean AT2R antibody
| Median AT2R antibody levels (U/mL) | Mean AT2R antibody levels (U/mL) | |
|---|---|---|
| Systemic lupus erythematosus (Group 3) | 80.8 (range: 6.3–84.2) | 64.12 ± 26.95 |
| p-ANCA vasculitis (Group 8) | 8.55 (range: 3.3–57.6) | 12.28 ± 13.48 |
| c-ANCA vasculitis (Group 7) | 5.7 (range: 1.8–56.3) | 7.83 ± 8.70 |
| Mesangial proliferative (non-IgA) glomerulonephritis (Group 5) | 5.6 (range: 1.7–60.6) | 13.95 ± 22.93 |
| IgA nephropathy (Group 4) | 4.65 (range: 2–17.9) | 6.26 ± 4.39 |
| Membranous glomerulonephritis (Group 1) | 4.55 (range: 1.1–11) | 5.05 ± 2.95 |
| Focal segmental glomerulosclerosis (Group 2) | 4.5 (range: 1.3–16.4) | 5.71 ± 4.28 |
| Control group (Group 6) | 5.9 (range: 2.7–45.5) | 9.72 ± 11.88 |